Transforming clinical development, diagnostics, and precision medicine in neurology with AI.
First, NeuraLight uses signal processing to augment standard video resolution to attain sub-pixel accuracy and enable high-precision measurements. By applying both machine learning and signal processing, NeuraLight can normalize various lighting conditions and adjust for movement, which is especially important for patients with conditions like Parkinson’s. The measurements extracted from this method are objective, sensitive, and reliable - unlike current subjective approaches to neurological evaluation. Second, NeuraLight’s novel, patent-pending approach is device-agnostic, which means that it does not require specific hardware. The technology can be seamlessly integrated into research facilities with existing video recording tools, significantly reducing the friction typically associated with pharma and clinicians adopting new tools. Finally, NeuraLight is actively building the world’s largest, proprietary, de-identified oculometric database. This database serves as a benchmark and a potent source to surface novel insights. Pharma companies and academic institutions can leverage NeuraLight’s insights to optimize patient selection and stratification, reduce the size of the trial, shorten the length of the clinical trial, and increase therapies’ probabilities of success.
You can’t improve what you don’t measure, and currently, there is no objective and sensitive way to measure the majority of neurological disorders, which is why it’s so hard to develop disease-modifying drugs for these disorders. In fact, today there exist very few disease-modifying treatments for neurodegenerative conditions because current standards for neurological evaluation are subjective in nature and don’t allow researchers to accurately, objectively, and sensitively measure disease progression. Studies in, e.g. Parkinson’s, show that if the same patient is evaluated for a neurological disorder on the same day by two different doctors, the doctors disagree with each other’s (UPDRS scale) assessment 25 percent of the time. Not only does this compromise treatment and leave patients in the dark about the true state of their neurological health, but it creates a massive barrier for pharma R&D. The inability to objectively track the progression of the neurodegenerative disease leaves scientists unsure about whether their trial drug is helping, hurting, or having no effect on patients. Further, around 25%of patients in clinical trials actually don’t have the disease that the drug is addressing due to insufficient evaluation methods. In a Parkinson’s trial cohort of 1000 participants, 250-300 may not actually have Parkinson’s. Thus, trial results could fall short of statistical significance even when the drug is extremely effective – reducing the chance to advance a potentially life-changing medicine. NeuraLight’s platform allows researchers to objectively, sensitively, and accurately evaluate trial participants’ neurological health statuses to advance treatments for Alzheimer’s, ALS, Parkinson’s, and MS.
In the near future, we will be releasing results from our healthy patient study. At our labs in Tel-Aviv, Israel, we’ve measured thousands of healthy volunteers in our efforts to build the world's largest oculometric database. In collaboration with NeuroSense, NeuraLight is currently involved in the Phase IIb PARADIGM trial, which is a double-blind, placebo-controlled study evaluating the efficacy of NeuroSense’s lead combination drug candidate, PrimeC, in the treatment of ALS. The NeuroSense- NeuraLight collaboration entails sharing and tracking patient data to advance the identification and use of ALS digital biomarkers in a parallel study conducted by NeuraLight.
